“This collaboration is an exciting extension of our work over more than 17 years, empowering antibodies in order to provide new therapeutic options for cancer patients,” said ​, President and Chief Executive Officer of ​. “Unum’s innovative technology for a universal, antibody-directed cellular immunotherapy is differentiated from other engineered T-cell approaches, and may have broad applicability across a range of cancer targets. We are pleased to be collaborating with one of the most promising companies in the emerging field of cellular immunotherapy to develop new treatment options for cancer patients with unmet medical needs.”

“This collaborationUnum’s strategy is an exciting extensionto develop and commercialize a universal cellular immunotherapy that can be used in combination with a variety of our work over more than 17 years, empowering antibodies in order to provide new therapeutic options for cancer patients,attack a wide range of hematological and solid tumors,” said C" data-ad-field-type="b" data-ad-field-json='{"name":"Person C","type":"b","canGuess":{"name":false,"type":false}}'>​, President and Chief Executive Officer of _SGI:​. “Unum’s innovative technology for a universal, antibody-directed cellular immunotherapy is differentiated from other engineered“We believe that our unique approach has the potential to advance beyond the safety and efficacy limitations of current generation T-cell approaches,approaches. We are delighted to collaborate with ​ in the development of ACTR therapies. Their leadership in antibody-based therapies and may have broad applicability across a rangeexpertise in the development of cancer targets. We are pleasedtreatments will be invaluable as we work together to be collaborating with one of the most promising companies in the emerging field of cellular immunotherapybring potentially breakthrough therapies to develop new treatment options for cancer patients with unmet medical needs.patients.”